NEONATAL MEDICATION PROTOCOLS

SURFACTANT (PORCINE) – PORACTANT ALFA (CUROSURF)
Created by: NCCU
Date for review: Oct 2016

NCCU Clinical Guidelines
KEMH/PMH
Perth. Western Australia

DRUG:	**SURFACTANT (PORCINE) – PORACTANT ALFA (CUROSURF)**
PRESENTATION:	Vials: 120 mg / 1.5 mL 240 mg / 3 mL
ACTION & INDICATION:	Pulmonary surfactant derived from pigs and used for the prevention or treatment of respiratory distress syndrome, according to NCCU guidelines.
DOSE:	**Rescue treatment** Initial dose: 2.5mL/kg (200mg/kg) Subsequent doses: 1.25mL/kg (100mg/kg). Up to 2 subsequent doses at 12 hourly intervals may be administered. Maximum total dose: 400mg/kg **Prophylaxis** Initial dose: 1.25mL-2.5mL/kg 100mg – 200mg/kg) administered within 15 minutes of birth. Subsequent doses of 1.25mL (100mg) /kg may be given 6-12 hours after the first dose and then 12 hours later in babies who remain ventilator dependent. Maximum total dose: 300-400mg/kg
ADMINISTRATION:	**For intratracheal administration only**. Poractant is administered via a 5fg end hole catheter shortened to protrude just beyond the end of the ETT, above the carina. Poractant should **NOT** be instilled into a **main** stem bronchus. Administer as outlined in the NCCU “Surfactant Replacement Therapy Guidelines”.
ADVERSE EFFECTS:	Adverse effects associated with dosing procedure: Transient bradycardia, oxygen desaturation, ETT reflux, pallor, vasoconstriction, hypotension, ETT blockage, hypertension, hypocarbia, hypercarbia, apnoea.
COMMENTS:	Warm vial to room temperature before use. Do not use artificial warming methods. Do not shake. Store open and unopened vials at 2 - 8ºC. Discard 12 hours after opening. Evaluate clinical condition before and for 30 minutes after each dose
REFERENCES:	Neofax 2013
DATE:	October 2013